Shattuck Labs (NASDAQ:STTK) Coverage Initiated at Leerink Partners

Equities research analysts at Leerink Partners began coverage on shares of Shattuck Labs (NASDAQ:STTK) in a research note issued to investors on Monday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $4.00 price target on the stock. Leerink Partners’ price objective would indicate a potential upside of 236.13% from the company’s current price.

Shattuck Labs Stock Down 1.7 %

STTK stock opened at $1.19 on Monday. Shattuck Labs has a twelve month low of $0.94 and a twelve month high of $11.76. The company has a market cap of $56.81 million, a P/E ratio of -0.78 and a beta of 1.66. The business’s fifty day moving average is $1.25 and its 200-day moving average is $1.63.

Hedge Funds Weigh In On Shattuck Labs

Institutional investors have recently modified their holdings of the stock. Zacks Investment Management acquired a new stake in shares of Shattuck Labs in the 4th quarter valued at approximately $25,000. Virtu Financial LLC bought a new position in shares of Shattuck Labs during the fourth quarter worth $30,000. Atom Investors LP bought a new stake in shares of Shattuck Labs in the 3rd quarter valued at $35,000. Readystate Asset Management LP acquired a new stake in Shattuck Labs during the 3rd quarter worth $39,000. Finally, Schonfeld Strategic Advisors LLC acquired a new position in Shattuck Labs in the fourth quarter valued at about $45,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.